share_log

RBC Capital Initiates Coverage On Fulcrum Therapeutics With Outperform Rating, Announces Price Target of $14

RBC Capital Initiates Coverage On Fulcrum Therapeutics With Outperform Rating, Announces Price Target of $14

加拿大皇家银行资本以跑赢大盘的评级启动对Fulcrum Therapeutics的报道,宣布目标股价为14美元
Moomoo 24/7 ·  03/13 12:31

RBC Capital analyst Gregory Renza initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform rating and announces Price Target of $14.

加拿大皇家银行资本分析师格雷戈里·伦扎以跑赢大盘的评级开始对Fulcrum Therapeutics(纳斯达克股票代码:FULC)进行报道,并宣布目标股价为14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发